Detalhe da pesquisa
1.
Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT).
Dis Model Mech
; 13(2)2020 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32066568
2.
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.
Ann Neurol
; 63(5): 561-71, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18335515
3.
The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development.
Orphanet J Rare Dis
; 10: 49, 2015 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25902795
4.
A decade of optimizing drug development for rare neuromuscular disorders through TACT.
Nat Rev Drug Discov
; 19(1): 1-2, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31907422
5.
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients.
J Bone Joint Surg Am
; 84(12): 2123-34, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12473698
6.
Pathways activated during human asthma exacerbation as revealed by gene expression patterns in blood.
PLoS One
; 6(7): e21902, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21779351
7.
Large clinical trials in musculoskeletal trauma: are they possible? Lessons learned from the international study of the use of rhBMP-2 in open tibial fractures.
J Bone Joint Surg Am
; 87(1): 218-22, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15634835
8.
Challenges in drug development for muscle disease: a stakeholders' meeting.
Muscle Nerve
; 35(1): 8-16, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17068768
9.
Clinical evaluation of recombinant human bone morphogenetic protein-2.
Clin Orthop Relat Res
; (395): 110-20, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11937870